Seguridad cardiovascular de los antidiabéticos no insulínicos: hechos y promesas

espanolLos antidiabeticos no insulinicos son farmacos de uso muy extendido en los pacientes con diabetes tipo 2, cuyo efecto sobre la reduccion del riesgo cardiovascular ha sido objeto de controversia. En el ano 2008, ante la evidencia del riesgo cardiovascular derivado del uso de algunos de ellos, la Food and Drug Administration norteamericana publico una directriz sobre la necesidad de realizar estudios de seguridad cardiovascular. Ello ha contribuido a disponer de mas evidencia, de manera que en el momento actual existen dos familias de farmacos que podrian reducir el riesgo cardiovascular. Estos datos recientes nos permiten anadir, al objetivo de controlar la glucemia, el de reducir la morbimortalidad cardiovascular. No obstante, la investigacion continua con el desarrollo de nuevos estudios a largo plazo. EnglishNon insulin antidiabetic drugs are widely used in patients with type 2 diabetes. However, the drugs’ effect in terms of reducing cardiovascular risk has been the subject of controversy. In 2008, based on the evidence of cardiovascular risk resulting from the use of a number of non insulin antidiabetic drugs, the US Food and Drug Administration published directives on the need to perform cardiovascular safety studies. These directives have helped obtain more evidence, such that at present there are 2 families of drugs that can reduce cardiovascular risk. These recent data have helped us add the reduction of cardiovascular morbidity and mortality to the objective of controlling blood glucose. Nevertheless, research continues with the development of new long-term studies.